Get started
Author

Divya Samineni

Observed names: D. Samineni, Samineni, Divya
Institution: Genentech
ORCID: 0000-0001-6300-2044
Observed ORCID: 0000-0001-6300-2044
OpenAlex ID: A5018886495
A phase 2 study of venetoclax plus R-CHOP as first-line treatment for patients with diffuse large B-cell lymphoma
2020 · Franck Morschhauser, Pierre Feugier, et al. · Blood · 166
Cevostamab Monotherapy Continues to Show Clinically Meaningful Activity and Manageable Safety in Patients with Heavily Pre-Treated Relapsed/Refractory Multiple Myeloma (RRMM): Updated Results from an Ongoing Phase I Study
2021 · Suzanne Trudel, Adam D Cohen, et al. · Blood · 165
Venetoclax plus R- or G-CHOP in non-Hodgkin lymphoma: results from the CAVALLI phase 1b trial
2019 · Andrew D. Zelenetz, Gilles Salles, et al. · Blood · 136
Phase I Study of DMOT4039A, an Antibody–Drug Conjugate Targeting Mesothelin, in Patients with Unresectable Pancreatic or Platinum-Resistant Ovarian Cancer
2016 · Colin D. Weekes, Laetitia E. Lamberts, et al. · Molecular Cancer Therapeutics · 109
A randomized trial of the efficacy and safety of quilizumab in adults with inadequately controlled allergic asthma
2016 · Jeffrey M. Harris, Romeo Maciuca, et al. · Respiratory Research · 104
PDF
A randomized trial of quilizumab in adults with refractory chronic spontaneous urticaria
2016 · Jeffrey M. Harris, Christopher R. Cabanski, et al. · Journal of Allergy and Clinical Immunology · 78
Initial Clinical Activity and Safety of BFCR4350A, a FcRH5/CD3 T-Cell-Engaging Bispecific Antibody, in Relapsed/Refractory Multiple Myeloma
2020 · Adam D. Cohen, Simon J Harrison, et al. · Blood · 77
Model‐Informed Therapeutic Dose Optimization Strategies for Antibody–Drug Conjugates in Oncology: What Can We Learn From US Food and Drug Administration–Approved Antibody–Drug Conjugates?
2021 · Michael Z. Liao, Dan Lu, et al. · Clinical Pharmacology & Therapeutics · 76
Phase I study of the anti-FcRH5 antibody-drug conjugate DFRF4539A in relapsed or refractory multiple myeloma
2019 · A. Keith Stewart, Amrita Y. Krishnan, et al. · Blood Cancer Journal · 63
PDF
Clinical pharmacology of vc-MMAE antibody–drug conjugates in cancer patients: learning from eight first-in-human Phase 1 studies
2019 · Chunze Li, Cindy Zhang, et al. · mAbs · 61
Phase Ia Study of Anti-NaPi2b Antibody–Drug Conjugate Lifastuzumab Vedotin DNIB0600A in Patients with Non–Small Cell Lung Cancer and Platinum-Resistant Ovarian Cancer
2019 · David E. Gerber, Jeffrey R. Infante, et al. · Clinical Cancer Research · 56
Physiologically Based Pharmacokinetic Modeling as a Tool to Predict Drug Interactions for Antibody-Drug Conjugates
2014 · Yuan Chen, Divya Samineni, et al. · Clinical Pharmacokinetics · 49
CAMMA 2: A phase I/II trial evaluating the efficacy and safety of cevostamab in patients with relapsed/refractory multiple myeloma (RRMM) who have triple-class refractory disease and have received a prior anti-B-cell maturation antigen (BCMA) agent.
2023 · Shaji Kumar, Carlos R. Bachier, et al. · Journal of Clinical Oncology · 47
Steady‐State Pharmacokinetic Interactions of Darunavir/Ritonavir With Lipid‐Lowering Agent Rosuvastatin
2011 · Divya Samineni, Pankaj B. Desai, et al. · The Journal of Clinical Pharmacology · 36
Dose Optimization in Oncology Drug Development: An International Consortium for Innovation and Quality in Pharmaceutical Development White Paper
2024 · Divya Samineni, Karthik Venkatakrishnan, et al. · Clinical Pharmacology & Therapeutics · 34
Phase 1b study of anti-NaPi2b antibody-drug conjugate lifastuzumab vedotin (DNIB0600A) in patients with platinum-sensitive recurrent ovarian cancer
2020 · Kathleen N. Moore, Michael J. Birrer, et al. · Gynecologic Oncology · 33
PDF
Venetoclax Plus Rituximab, Cyclophosphamide, Doxorubicin, Vincristine and Prednisolone (R-CHOP) Improves Outcomes in BCL2-Positive First-Line Diffuse Large B-Cell Lymphoma (DLBCL): First Safety, Efficacy and Biomarker Analyses from the Phase II CAVALLI Study
2018 · Franck Morschhauser, Pierre Feugier, et al. · Blood · 33
Anti-CD79B Antibody–Drug Conjugate DCDS0780A in Patients with B-Cell Non-Hodgkin Lymphoma: Phase 1 Dose-Escalation Study
2022 · Alex F. Herrera, Manish R. Patel, et al. · Clinical Cancer Research · 32
Prediction of Human Pharmacokinetics of Antibody–Drug Conjugates From Nonclinical Data
2019 · Chunze Li, Cindy Zhang, et al. · Clinical and Translational Science · 32
PDF
Development and Translational Application of an Integrated, Mechanistic Model of Antibody-Drug Conjugate Pharmacokinetics
2016 · Siddharth Sukumaran, Crystal Zhang, et al. · The AAPS Journal · 27
Physiologically Based Pharmacokinetic Model‐Informed Drug Development for Polatuzumab Vedotin: Label for Drug‐Drug Interactions Without Dedicated Clinical Trials
2020 · Divya Samineni, Hao Ding, et al. · The Journal of Clinical Pharmacology · 25
Quantification of human hepatocyte cytochrome P450 enzymes and transporters induced by HIV protease inhibitors using newly validated LC‐MS/MS cocktail assays and RT‐PCR
2012 · Li Liu, Ganesh M. Mugundu, et al. · Biopharmaceutics & Drug Disposition · 21
PDF
A Phase I dose‐escalation study of DCLL9718S , an antibody‐drug conjugate targeting C ‐type lectin‐like molecule‐1 ( CLL ‐1) in patients with acute myeloid leukemia
2021 · Naval Daver, Amandeep Salhotra, et al. · American Journal of Hematology · 20
Impact of Shed/Soluble targets on the PK/PD of approved therapeutic monoclonal antibodies
2016 · Divya Samineni, Sandhya Girish, et al. · Expert Review of Clinical Pharmacology · 20
Time‐to‐Event Modeling of Peripheral Neuropathy: Platform Analysis of Eight Valine‐Citrulline‐Monomethylauristatin E Antibody–Drug Conjugates
2019 · Matts Kågedal, Divya Samineni, et al. · CPT Pharmacometrics & Systems Pharmacology · 19
PDF
Works count: 77
Citation count: 1,652
H-index: 21
I10-index: 32
Year
Topic
Type